A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
General assessment of AEs, Pulmonary Function tests and chest CTScan.
Screening, Day 1, Day 10, Day 22, Day 28
Srdan Verstovsek, MD
United States: Food and Drug Administration
|Research Site||Albany, New York|
|Research Site||Abilene, Texas|